Clinical Trials Logo

Clinical Trial Summary

Liver resection has improved health outcomes in patients with hepatocellular carcinoma (HCC) in Singapore and worldwide. However, due to acute ischaemia/reperfusion injury (IRI) to the liver at the time of surgery, patients still experience significant morbidity and mortality. Therefore, novel therapies are required to protect the liver against acute IRI during partial hepatectomy. Remote ischaemic conditioning (RIC) using transient limb ischaemia/reperfusion has been shown to protect the liver in experimental animal studies. In the ERIC-LIVER trial the investigators investigate whether RIC can reduce liver injury and preserve liver function in patients with HCC undergoing partial hepatectomy.


Clinical Trial Description

Liver resection has improved health outcomes in patients with hepatocellular carcinoma (HCC) in Singapore and worldwide. However, due to acute ischaemia/reperfusion injury (IRI) to the liver at the time of surgery, patients still experience significant morbidity and mortality. Therefore, novel therapies are required to protect the liver against acute IRI during partial hepatectomy. Remote ischaemic conditioning (RIC) using transient limb ischaemia/reperfusion has been shown to protect the liver in experimental animal studies. In the ERIC-LIVER trial the investigators investigate whether RIC can reduce liver injury and preserve liver function in patients with HCC undergoing partial hepatectomy.

50 patients with HCC undergoing partial hepatectomy will be randomised to receive either RIC (four-5 minute arm cuff inflations/deflations) or sham control (four-5 minute arm cuff simulated inflations/deflations) after induction of anesthesia and prior to surgical incision. The primary endpoint of the study will be acute liver injury assessed by serum transaminases measured at 24 hours post-resection. Secondary endpoints will include liver function in subset of patients (N=24, assessed by indocyanine green [ICG] clearance measured at 24 hours post-resection), incid ence of liver failure, episodes of confirmed sepsis, acute kidney injury, intensive care unit and hospital stay, and quality of life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03594929
Study type Interventional
Source Singapore General Hospital
Contact Jin Yao Teo
Phone 63214515
Email teo.jin.yao@singhealth.com.sg
Status Recruiting
Phase N/A
Start date August 15, 2016
Completion date April 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03971201 - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion Phase 2
Recruiting NCT05489250 - The PLATON Network
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Terminated NCT00878215 - Clinical Application of Image-Guided Liver Surgery Phase 2
Completed NCT04212286 - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC N/A
Recruiting NCT05992220 - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion Phase 2
Completed NCT02073435 - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting NCT01522937 - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer Phase 2
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Active, not recruiting NCT04166240 - Measuring and Improving the Safety of Test Result Follow-Up N/A
Withdrawn NCT02288507 - Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Phase 1
Terminated NCT03026803 - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer Phase 2
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting NCT05100082 - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting NCT03195699 - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers Phase 1
Completed NCT02616692 - HCC Patient Preferences in Japan N/A
Active, not recruiting NCT03132792 - AFPᶜ³³²T in Advanced HCC Phase 1
Not yet recruiting NCT06239194 - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT01849588 - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Phase 4